ArticleAmerican journal of translational research2015
MicroRNA-130a expression is decreased in Xinjiang Uygur patients with type 2 diabetes mellitus.
Article in American journal of translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus.International journal of molecular sciences · 2017Pooled it
- Dysregulated microRNAs in type 2 diabetes and breast cancer: Potential associated molecular mechanisms.World journal of diabetes · 2024Review
- MicroRNAs as Biomarkers for Coronary Artery Disease Related to Type 2 Diabetes Mellitus-From Pathogenesis to Potential Clinical Application.International journal of molecular sciences · 2022Review
- Regulation of microRNAs in Alzheimer´s disease, type 2 diabetes, and aerobic exercise training.Metabolic brain disease · 2022Review
- Role of miRNAs in the pathogenesis of T2DM, insulin secretion, insulin resistance, and β cell dysfunction: the story so far.Journal of physiology and biochemistry · 2020Review
- Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect.Metabolites · 2020Article
- Exercise Training-Induced Changes in MicroRNAs: Beneficial Regulatory Effects in Hypertension, Type 2 Diabetes, and Obesity.International journal of molecular sciences · 2018Review
- MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.Cell proliferation · 2017Article
- MicroRNAs-Dependent Regulation of PPARs in Metabolic Diseases and Cancers.PPAR research · 2017Review
- miR-217 Is a Useful Diagnostic Biomarker and Regulates Human Podocyte Cells Apoptosis via Targeting TNFSF11 in Membranous Nephropathy.BioMed research international · 2017Article
- Serum miR-200c and miR-371-5p as the Useful Diagnostic Biomarkers and Therapeutic Targets in Kawasaki Disease.BioMed research international · 2017Article
- FGF-16 protects against adverse cardiac remodeling in the infarct diabetic heart.American journal of translational research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsMicroRNAs play important roles in energy metabolism, insulin synthesis, insulin transport and the development of diabetes. This study aims to investigate the expression and effect of microRNA-130a in Uygur patients with type 2 diabetes mellitus (T2DM). MATERIALS AND
methodsPeripheral blood and omental adipose tissues were collected from individuals with normal glucose tolerance and patients with T2DM. The microRNA expression profile of peripheral blood was established by microarray analysis. The differentially expressed microRNAs and possible target genes were identified by bioinformatics analysis. MicroRNA-130a mimics and inhibitors were transfected into 3T3-L1 preadipocytes.
resultsOur results showed that microRNA-130a expression level was significantly decreased in peripheral blood and omental adipose tissues of T2DM patients (P < 0.01). Peroxisome proliferator-activated receptors γ (PPARγ) were predicted as target genes of microRNA-130a. This prediction was verified by the results that PPARγ mRNA expression in omental adipose tissues of T2DM patients were significantly increased (P < 0.01). The glucose consumption level after microRNA-130a transfection was significantly decreased (P < 0.05). And, microRNA-130a mimics inhibited PPARγ expression at both mRNA and protein level, further suggesting that PPARγ is a target gene of microRNA-130a. Additionally, adiponectin, lipoprotein lipase, CCAAT enhancer binding protein α, and the downstream genes of PPARγ, were significantly decreased after microRNA-130a mimics transfection.
conclusionsIn conclusion, microRNA-130a is decreased in Uygur patients with T2DM and it may play a role in T2DM through targeting PPARγ.
Indexed as
Identifiers
26692941PMC4656774W2200807516What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.